Come join me for lunch at the Mad Hedge Fund Trader’s Global Strategy Update, which I will be conducting in Sydney Australia at 12:30 PM on Tuesday, February 4, 2020.
An excellent meal will be followed by a wide-ranging discussion and an extended question-and-answer period.
I’ll be giving you my up-to-date view on stocks, bonds, currencies, commodities, precious metals, energy, and real estate.
And to keep you in suspense, I’ll be throwing a few surprises out there too.
Tickets are available for $233.
The lunch will be held at an exclusive downtown hotel the details of which will be emailed with your purchase confirmation.
I look forward to meeting you and thank you for supporting my research. To purchase tickets for this luncheon, please click here.
https://www.madhedgefundtrader.com/wp-content/uploads/2018/10/John-Thomas-Sydney.png345377Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-01-22 04:04:442020-02-05 10:01:52SOLD OUT - Tuesday, February 4 Sydney, Australia Global Strategy Luncheon
Occasionally, I discover a piece of research from one of my other Mad Hedge publications that is so important that I send it out to everyone immediately.
Today piece from the Mad Hedge Biotech & Health Care Letter is one of the instances. It makes the case and provides the numbers as to why Biotech & Health Care will be one of two dominant sector to follow for the next decade. It also is a key plank in my argument for a return of a new Golden Age and a second “Roaring Twenties.”
Here it is.
Biotech investors, take note: 2019 was a great year for the industry, but the best is yet to come.
In the final three months of 2019, the biotech sector grew by 32% -- notably outpacing the pharmaceutical industry, which only recorded a 9.5% gain.
However, the biotechnology sector is estimated to grow substantially in 2020, and reach over $775 billion in revenue by 2024 as more and more treatments for previously incurable diseases get discovered.
Looking at all the progress in the biotechnology space, this could even be the year we’d finally discover the cure to many life-threatening and debilitating conditions like cancer and Alzheimer’s disease.
With all these technological advancements, two revolutionary tools have been overhauling the entire biotechnology and healthcare industry from the ground up: precision medicine and CRISPR. Actually, the impressive growth of the biotechnology industry has been largely attributed to the excitement generated by the gene-editing sector.
While the majority of companies concentrating on the human genome are still in the research phase, the growth of this industry is undeniable.
Here’s tangible proof.
Just 20 years ago, reading all the DNA of a single person cost approximately $3 billion. Now, this price is down to only $1,000. In the future, this number will go even lower at $100. There are now gigantic factories in China sequencing DNA for companies like Ancestry.com and 23andMe.
This is just one example of how the biotechnology industry has grown by leaps and bounds. It’s also the reason behind the surge of CRISPR shares.
In effect, the specialists in this niche, including Crispr Therapeutics (CRSP), Bluebird Bio (BLUE), and Editas Medicine (EDIT), are amplifying their efforts in 2020.
Among the specialist companies, CRISPR Therapeutics is considered as one of the frontrunners -- if not the top stock. This is because compared to its rivals, which are still in preclinical phases of development, CRISPR Therapeutics’ already has two drugs going through Phase 1 trials: CTX001 and CTX110.
The promising results of the company’s research resulted in a 113% rise in shares last year, with the bulk of the surge starting in October. In fact, CRISPR Therapeutics’ performance had been so impressive that its market cap reached $3.4 billion.
CTX001 is created to target patients suffering from genetic blood disorders, specifically sickle-cell disease and transfusion-dependent beta-thalassemia.
Meanwhile, CTX110 is a CAR-T treatment. The process involves the extraction of immune cells from the patient. These are then retrained and later re-introduced to the human body.
CRISPR Therapeutics’ CAR-T treatment is anticipated to be offered at a cheaper price compared to the other CAR-T therapies.
Both Novartis (NVS) and Gilead Sciences (GILD) are pursuing the same treatment. However, the cost of the therapy from the latter two is expected to reach as much as $475,000 for every patient annually.
Apart from CTX001 and CTX110, CRISPR Therapeutics has two more immunology candidates, currently dubbed CTX120 and CTX130.
If both phase trials succeed, these will bring massive home runs for CRISPR Therapeutics, especially since the cancer immunology market is expected to reach $127 billion by 2026. Over the next 10 years, this niche is estimated to reach $25 trillion in sales.
Among the gene-editing treatments under development today, CRISPR is projected to grow tenfold in the number of applications and potentially curing 89% of disease-causing genetic variations by 2026.
Taking this pace into consideration, the valuation for this market is expected to grow from $551 million in 2017 to reach roughly $3.1 billion by 2023 and $6 billion by 2025.
Meanwhile, precision medicine as a whole is estimated to show a significant jump from $48.6 billion in 2018 to $84.6 billion by 2024. In 2028, this market is expected to rake in $216 billion.
Hence, further success with CTX001 and CTX110 along with additional treatments in the drug pipeline would all but guarantee that Crispr Therapeutics could beat the market again in 2020.
https://www.madhedgefundtrader.com/wp-content/uploads/2020/01/biotech.png337506Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-01-22 04:02:382020-05-11 14:14:25Why There’s Another Double in CRISPR Therapeutics
(LAST CHANCE TO ATTEND THE WEDNESDAY FEBRUARY 3 BRISBANE, AUSTRALIA STRATEGY LUNCHEON)
(MARKET OUTLOOK FOR THE WEEK AHEAD, or DOW 120,000 HERE WE COME!)
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png00Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-01-21 10:06:022020-01-21 10:42:51January 21, 2020
Come join me for lunch at the Mad Hedge Fund Trader’s Global Strategy Luncheon, which I will be conducting in Brisbane, Australia on Monday, February 3, 2020 at 12.30 PM.
An excellent meal will be followed by a wide-ranging discussion and a question-and-answer period. I’ll be giving you my up-to-date view on stocks, bonds, currencies, commodities, precious metals, energy, and real estate.
I also hope to provide some insight into America’s opaque and confusing political system. And to keep you in suspense, I’ll be throwing a few surprises out there too.
Tickets are available for $234.
The lunch will be held at an exclusive hotel in downtown Brisbane, the location of which will be emailed with your purchase confirmation.
I look forward to meeting you and thank you for supporting my research. To purchase tickets for this luncheon, please click here.
https://www.madhedgefundtrader.com/wp-content/uploads/2019/05/brisbane.png352629Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-01-21 10:04:352020-02-03 17:42:12SOLD OUT - Monday, February 3 Brisbane, Australia Global Strategy Luncheon
My forecast for the Dow Average for 2030 is 120,000, which I have been predicting since the market bottomed in March, 2010, up 313% from here.
My problem is that so many people have recently come over to my own line of thinking that it has become impossible for me to take advantage of it.
The only chance you had to get into the market in 2020 was when the president ordered the execution of an Iranian general. Even then, the Dow dropped only 400 points, a miniscule 1.4%, and the Mad Hedge Market Timing Index backed off a smidgen, from 93 to 87. It then took off again like a scalded chimp.
Every professional trader I know to a man and woman is out of the market, stunned by euphoria run amok. We all know this ends in tears. The only question is how many pennies you can pick up before the steamroller runs you over. Option implied volatilities are at five-year lows, never a good place to trade.
I’ve been telling big hedge funds to give control of their funds over to their youngest, least experienced, and dumbest traders. It is only they who can make money in this environment, those who have never seen markets go down. I gave the same advice in 2007, 1999, and 1987. Before that, nobody cared what I thought.
So there is nothing left for us to do here but exercise rock-solid discipline, while many others are dancing on the tables. You can take solace in the knowledge that those buying stocks here will be puking them back out when markets are down 5%-10%. Whether that takes place next week or next month is anyone’s guess.
US stocks have risen 40% in 12 months on falling earnings, taking earnings multiples from 14 to 20. And the Volatility Index (VIX) stands at a near-decade low of $12. Am I missing something?
Risk is extreme, with Wharton’s Uber bull, Jeremy Siegal expecting the Dow Average to hit 30,000 in the next ten days. The top five stocks are posting most of the gains. With the Mad Hedge Marketing Timing Index at a lofty 93 last week, how many pennies can you pick up in front of the steamroller? I’m staying in cash with a small long volatility position I bought at a half-decade low.
It’s Q4 Earnings Season, with the big banks kicking off on Tuesday, generally bringing in satisfying result. Will aggregate earnings be flat or show a small gain? Most companies have already cut forecasts enough so 80% will beat predictions. The problem is how much is in the price?
Tesla hit $550, as the stock continues its parabolic run. It’s definitely getting overcooked here with a nonstop $320 run since June. Look for a Q1 sales pullback as the steroids of the rush to beat the 2019 end of federal subsidies wears off. That will be your next chance to buy. My decade target is $2,500 a share.
The Big biotech & healthcare conference last week in San Francisco organized by JP Morgan usually marks an interim top for this sector. If you need short term profits, better now than never. Some of our names have doubled and many are up 25% since the launch of the Mad Hedge Biotech & Healthcare Letter in September. Click here to subscribe.
US Consumer Prices rose in December, up 0.2%, following hotter months. The CPI is up a miniscule 2.3% YOY. With inflation moderating, Goldilocks lives!
Blackrock says climate change will remake investment. The $7 trillion manager is rolling out a new line of ETFs focusing on ESG, or Environmental, Social, and Governance investing. ESG has risen from 1% to 3.6% of all funds in a year. Investing in traditional carbon-based companies is essentially banned.
The Trade wars are still costing us money, with the World Bank cutting growth forecasts for 2020 and 2021. Almost every economic data point is weaker than two years ago. Only jobs remain robust. The Fed says that manufacturing has been hardest hit. How long will the pain continue?
Student debt tops $1.6 trillion making it the next subprime crisis. Most borrowers are only paying monthly interest and not a penny towards principal. That’s millions of consumers that are out of the economy and not spending. I paid off my loans 40 years ago with a single check. The loan officer asked, “You want to do what!?”
Housing starts soared to a 13-year high, up a blockbuster 16.9% in December to 1.608 million units. The industry is cashing in on massive Fed expansion of the monetary base and ultra-low interest rates. Buyers recently enrich by rocketing stock prices are stepping up as the “wealth effect” explodes.
My Global Trading Dispatch performance held steady at +356.91% for the past ten years, an all-time high. My 2019 year-to-date came in at a final +55.86%. We closed out December with a market beating +4.97% profit. My ten-year average annualized profit ground back up to +35.28%.
Option values are at five years low, making the call and put spreads I usually do the least attractive since 2015. My true risk-free trades take place when the Volatility Index (VIX) rises above $20. It has been hugging $12 for the past two weeks.
You don’t need me, or any other advisor, when markets rise every day. When they don’t, you financial life depends on me.
The coming week will be pretty dismal on the data front, with a national holiday and some other minor releases.
On Monday, January 20, market was closed for Martin Luther King Day.
On Tuesday, January 21, no data releases of note take place.
On Wednesday, January 22, at 8:00 AM, Existing Home Sales for December are out, the most important housing number of the month.
On Thursday, January 23 at 8:30 AM, Weekly Jobless Claims are announced.
On Friday, January 24, The Baker Hughes Rig Count is released at 2:00 PM.
As for me, I spent Saturday hiking 12 miles around San Francisco with 20 Boy Scouts, instructing them on the finer points of navigating by compass. I found a lot of lesser sights I had never seen before and stumbled across several charming postage stamp-sized community parks. We ended up at Ghirardelli Square where we consumed a celebratory hot fudge sundae.
And what did we come across during our explorations? A naked man with a selfie stick walking down the Embarcadero making a YouTube video!
Only in San Francisco.
Good Luck and Good Trading
John Thomas
CEO & Publisher
The Diary of a Mad Hedge Fund Trader
https://www.madhedgefundtrader.com/wp-content/uploads/2020/01/john-thomas-blue.png727520Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-01-21 10:02:182020-05-11 14:14:14The Market Outlook for the Week Ahead or Dow 120,000 Here We Come
I am always watching for market-topping indicators and I have found a whopper. The number of new IPOs from technology mega unicorns is about to explode. And not by a little bit but a large multiple, possibly tenfold.
Some 220 San Francisco Bay Area private tech companies valued by investors at more than $700 billion are likely to thunder into the public market next year, raising buckets of cash for themselves and minting new wealth for their investors, executives, and employees on a once-unimaginable scale.
Will it kill the goose that laid the golden egg?
Newly minted hoody-wearing millionaires are about to stampede through my neighborhood once again, buying up everything in sight.
That will make 2020 the biggest year for tech debuts since Facebook’s gargantuan $104 billion initial public offering in 2012. The difference this time: It’s not just one company but hundreds that are based in San Francisco, which could see a concentrated injection of wealth as the nouveaux riches buy homes, cars and other big-ticket items.
If this is not ringing a bell with you, remember back to 2000. This is exactly the sort of new issuance tidal wave that popped the notorious Dotcom Bubble.
And here is the big problem for you. If too much money gets sucked up into the new issue market, there is nothing left for the secondary market, and the major indexes can fall by a lot. Granted, probably only $100 billion worth of stock will be actually sold, but that is still a big nut to cover.
The onslaught of IPOs includes home-sharing company Airbnb at $31 billion, data analytics firm Palantir at $20 billion, and FinTech company Stripe at $20 billion.
The fear of an imminent recession starting sometime in 2020 or 2021 is the principal factor causing the unicorn stampede. Once the economy slows and the markets fall, the new issue market slams shut, sometimes for years as they did after 2000. That starves rapidly growing companies of capital and can drive them under.
For many of these companies, it is now or never. They have to go public and raise new money or go under. The initial venture capital firms that have had their money tied up here for a decade or more want to cash out now and roll the proceeds into the “next big thing,” such as blockchain, healthcare, or artificial intelligence. The founders may also want to raise some pocket money to buy that mansion or mega yacht.
Or, perhaps they just want to start another company after a well-earned rest. Serial entrepreneurs like Tesla’s Elon Musk (TSLA) and Netflix’s Reed Hastings (NFLX) are already on their second, third, or fourth startups.
And while a sudden increase in new issues is often terrible for the market, getting multiple IPOs from within the same industry, as is the case with ride-sharing Uber and Lyft, is even worse. Remember the five pet companies that went public in 1999? None survived.
Some 80% of all IPOs lost money last year. This was definitely NOT the year to be a golfing partner or fraternity brother with a broker.
What is so unusual in this cycle is that so many firms have left going public to the last possible minute. The desire has been to milk the firms for all they are worth during their high growth phase and then unload them just as they go ex-growth.
Also holding back some firms from launching IPOs is the fear that public markets will assign a lower valuation than the last private valuation. That’s an unwelcome circumstance that can trigger protective clauses that reward early investors and punish employees and founders. That happened to Square (SQ) in its 2015 IPO.
That’s happening less and less frequently: In 2019, one-third of IPOs cut companies’ valuations as they went from private to public. In 2019, that ratio has dropped to one in six.
Also unusual this time around is an effort to bring in more of the “little people” in the IPO. Gig economy companies like Uber and Lyft have lobbied the SEC for changes in new issue rules that enabled their drivers to participate even though they may be financially unqualified. They were all hit with losses of a third once the companies went public.
As a result, when the end comes, this could come as the cruelest bubble top of all.
https://www.madhedgefundtrader.com/wp-content/uploads/2019/03/unicorn.png402402Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-01-16 11:02:172020-05-11 14:13:47Will the Unicorns Kill the Bull Market?
Come join me for lunch at the Mad Hedge Fund Trader’s Global Strategy Update, which I will be conducting in Honiara in the Solomon Islands at 12:30 PM on Friday, January 31, 2020.
An excellent meal will be followed by a wide-ranging discussion and an extended question-and-answer period.
I’ll be giving you my up-to-date view on stocks, bonds, currencies, commodities, precious metals, energy, and real estate.
And to keep you in suspense, I’ll be throwing a few surprises out there too.
Tickets are available for $299.
The lunch will be held at the only decent hotel in the Solomon Islands, one of the poorest countries in the world. Malaria is endemic, so bring your Malaria pills (start taking them three days before departure). Typhoid shots will also be helpful.
If you have any questions about the Guadalcanal luncheon, please email me at support@madhedgefundtrader.com. Just put “Guadalcanal Luncheon” in the subject line.
I look forward to meeting you and thank you for supporting my research. To purchase tickets for this luncheon, please click here.
When the Commandant of the Marine Corps asks for a favor, you say “Yes Sir” without hesitating. So when General David H. Berger called me and asked to represent him at the 78th annual memorial service for the 1942 Battle of Guadalcanal, I started booking my flight.
It seems I’m the only living Corps veteran who had both a father and an uncle fight at Guadalcanal, who also speaks Japanese. That will enable me to sympathize with the Japanese families attending the service who lost loved ones.
I have acted as a diplomatic representative for the Marine Corps for many decades. Over the years, I have met presidents, Medal of Honor winners, and Navaho code talkers. My favorite was always the annual D-Day memorials at the Normandy beaches where I usually participated in a flyover. For a history buff like me, it’s a dream come true. Plus, Normandy had better food.
Guadalcanal was the decisive battle of WWII. The Americans lost 7,000 men, 25 ships, and 175 planes. The Japanese lost 30,000 men, 25 ships, including a major battleship, and 450 planes. Before Guadalcanal, the Japanese had never lost a battle. After Guadalcanal, they never won. If the US had lost Guadalcanal, WWII would have continued until 1948 or 1949.
Dad on the Right
https://www.madhedgefundtrader.com/wp-content/uploads/2019/12/John-Thomas-senior.png377535Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-01-15 10:04:092020-01-27 11:45:13SOLD OUT - Friday, January 31, 2020 Guadalcanal Strategy Luncheon
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.
